Matthews Quoted on Mylan’s Potential DOJ Investigation

28 September 2016 CNBC News

CNBC

Partner James Matthews was quoted in a CNBC article, “Mylan ‘Incorrectly’ Classified EpiPens, Shortchanging Government: Regulators,” on September 28, 2016. The article discussed allegations that Mylan is shortchanging the government on rebates for sales of EpiPen through a misclassification resulting in shortfalls of many millions of dollars in rebates owed by Mylan to the Centers for Medicare and Medicaid Services. Matthews said if Mylan is found to have misclassified EpiPens, the company runs risks beyond, “simply repaying the amount of money they should have paid.” He explained that if the Justice Department brings a successful False Claims Act case against Mylan, “they have the ability to obtain very large, potentially massive penalties … for every violation of the False Claim Act. But beyond that, they have the ability to obtain injunctive relief. The United States could disqualify, could bar Mylan, from participating in any [federal government] programs going forward.”

Related Services

Insights

Bad Holiday Season News! Estimates of an increase of Cyberattacks 20%!
13 December 2019
Internet, IT & e-Discovery Blog
Driving the Future of Automotive Technology
12 December 2019
Manufacturing Industry Advisor
Massachusetts Governor Proposes Facility Fee Ban
12 December 2019
Health Care Law Today
American Rule Prevails; PTO May Not Collect In-House Attorneys' Fees as "Expenses"
12 December 2019
IP Litigation Current
ACCC 46th Annual Meeting & Cancer Center Business Summit
04-05 March 2020
Washington, D.C.
Foley/Deloitte Compliance and Privacy Officer Roundtable
27 February 2020
Boston, MA
Let’s Talk Compliance
24 January 2020
Orlando, FL
New England Alliance Annual Meeting
15-17 January 2020
Woodstock, VT